Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.
Lead Product(s): AB-729,Peginterferon Alfa 2A,Nivolumab
Therapeutic Area: Infections and Infectious Diseases Brand Name: AB-729
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Lead Product(s) : AB-729,Peginterferon Alfa 2A,Nivolumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to...
Brand Name : AB-729
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 21, 2023
Details:
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens including hepatitis B surface antigen which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.
Lead Product(s): AB-729,Peginterferon Alfa 2A
Therapeutic Area: Infections and Infectious Diseases Brand Name: AB-729
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Lead Product(s) : AB-729,Peginterferon Alfa 2A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens including hepatitis B surface antigen which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to r...
Brand Name : AB-729
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 13, 2022
Details:
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.
Lead Product(s): AB-729,Peginterferon Alfa 2A
Therapeutic Area: Infections and Infectious Diseases Brand Name: AB-729
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Lead Product(s) : AB-729,Peginterferon Alfa 2A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729
Details : AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to...
Brand Name : AB-729
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 30, 2022
Details:
Most patients had a robust decline in HBsAg that was maintained well after cessation of AB-729 treatment, mean log change from baseline to 24 weeks post last dose was approximately -1.5 log10 across cohorts.
Lead Product(s): AB-729,Peginterferon Alfa 2A
Therapeutic Area: Infections and Infectious Diseases Brand Name: AB-729
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Lead Product(s) : AB-729,Peginterferon Alfa 2A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™...
Details : Most patients had a robust decline in HBsAg that was maintained well after cessation of AB-729 treatment, mean log change from baseline to 24 weeks post last dose was approximately -1.5 log10 across cohorts.
Brand Name : AB-729
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 24, 2022
Details:
AB-729 is an RNA interference therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to virus.
Lead Product(s): AB-729,Peginterferon Alfa 2A
Therapeutic Area: Infections and Infectious Diseases Brand Name: AB-729
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Lead Product(s) : AB-729,Peginterferon Alfa 2A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress 2022
Details : AB-729 is an RNA interference therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respon...
Brand Name : AB-729
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 08, 2022
Details:
LIFT is a Phase 2a open-label study of 26 adult patients with chronic HDV treated with Lambda 180 mcg once weekly in combination with Lonafarnib 50 mg boosted with ritonavir 100 mg twice daily for 24 weeks.
Lead Product(s): Peginterferon Alfa 2A,Lonafarnib,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Pegasys
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Lead Product(s) : Peginterferon Alfa 2A,Lonafarnib,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LIFT is a Phase 2a open-label study of 26 adult patients with chronic HDV treated with Lambda 180 mcg once weekly in combination with Lonafarnib 50 mg boosted with ritonavir 100 mg twice daily for 24 weeks.
Brand Name : Pegasys
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 31, 2020
Details:
HDV Phase 3 D-LIVR Study is in Progress. Eiger is supplying Peginterferon Lambda and is assisting in the protocol design to initiate study.
Lead Product(s): Lonafarnib,Ritonavir,Peginterferon Alfa 2A
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Lead Product(s) : Lonafarnib,Ritonavir,Peginterferon Alfa 2A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : HDV Phase 3 D-LIVR Study is in Progress. Eiger is supplying Peginterferon Lambda and is assisting in the protocol design to initiate study.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD :
TE Code :
Brand Name : PEGASYS
Dosage Form : VIAL; SUBCUTANEOUS
Dosage Strength : 180UG/VIAL
Approval Date :
Application Number : 103964
RX/OTC/DISCN :
RLD :
TE Code :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RLD :
TE Code :
Brand Name : PEGASYS
Dosage Form : SYRINGE
Dosage Strength : 180U/5ML
Approval Date :
Application Number : 103964
RX/OTC/DISCN :
RLD :
TE Code :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Sweden
Brand Name : Pegasys
Dosage Form : SOLUTION FOR INJECTION IN PRE-FILLED
Dosage Strength : 180 MICROGRAM
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Pegasys
Dosage Form : SOLUTION FOR INJECTION IN PRE-FILLED
Dosage Strength : 135 MICROGRAMS
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Pegasys
Dosage Form : SOLUTION FOR INJECTION, PRE-FILLED SYRINGE
Dosage Strength : 90 MICROGRAMS
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Pegasys
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 135 MICROGRAMS
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Pegasys
Dosage Form : SOLUTION FOR INJECTION, PRE-FILLED SYRINGE
Dosage Strength : 135 MICROGRAMS
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Pegasys
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 180 MICROGRAM
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Pegasys
Dosage Form : SOLUTION FOR INJECTION, PRE-FILLED SYRINGE
Dosage Strength : 180 MICROGRAM
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Switzerland
Brand Name : Pegasys
Dosage Form : Inj Solution
Dosage Strength : 135mcg/0.5ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Switzerland
Brand Name : Pegasys
Dosage Form : Inj Solution
Dosage Strength : 180mcg/0.5ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
Regulatory Info :
Registration Country : Canada
Brand Name : PEGASYS
Dosage Form : SOLUTION
Dosage Strength : 180MCG/0.5ML
Packaging :
Approval Date :
Application Number : 2248077
Regulatory Info :
Registration Country : Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Pegasys
Dosage Form : injection
Dosage Strength : 180 microgram/0.5 mL
Packaging : 4
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Pegasys
Dosage Form : injection
Dosage Strength : 135 microgram/0.5 mL
Packaging : 4
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Pegasys
Dosage Form : injection
Dosage Strength : 135 microgram/0.5 mL
Packaging : 4
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Pegasys
Dosage Form : injection
Dosage Strength : 180 microgram/0.5 mL
Packaging : 4
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Pegasys
Dosage Form : injection
Dosage Strength : 135 microgram/0.5 mL
Packaging : 4
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Pegasys
Dosage Form : injection
Dosage Strength : 180 microgram/0.5 mL
Packaging : 4
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
21 Sep 2021
// CLINICALTRIALSARENA
https://www.clinicaltrialsarena.com/news/eiger-dsmb-progress-trial/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103964
20 Aug 2019
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/eiger-announces-fda-breakthrough-therapy-designation-for-peginterferon-lambda-for-treatment-of-hepatitis-delta-virus-infection-300903974.html
12 Aug 2019
// BIOSPECTRUMASIA
https://www.biospectrumasia.com/news/28/14205/ascletis-opens-clinical-development-shanghai-center.html
Global Sales Information
Finished Drug Prices
RX/OTC/DISCN : Class A
CPS Cito Pharma Services GmbH
Dosage Form : Inj Solution
Dosage Strength : 135mcg/0.5ml
Price Per Pack (Euro) : 617.82
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RX/OTC/DISCN : Class A
CPS Cito Pharma Services GmbH
Dosage Form : Inj Solution
Dosage Strength : 180mcg/0.5ml
Price Per Pack (Euro) : 706.02
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
FDF DOSSIERS
Reply
06 Oct 2021
Reply
02 Nov 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Share 
Comment (8)
